Price Chart

Executive Summary

Replimune Group is conducting a $150 million underwritten public offering of 9,701,490 shares of common stock and pre-funded warrants to purchase 2,736,340 shares, priced at $12.06 per share, at-the-market. Net proceeds of ~$140.5 million will fund the commercial launch of TUDRIQEV (RP1), recently granted accelerated FDA approval, and continued development of the RPx platform. The offering was taken down from a shelf registration filed 17 days ago that had flagged a 30% overhang from Baker Brothers affiliates' resale registration and a going-concern warning with cash runway only through Q1 2027. This dilutive capital raise adds near-term downside, extending the runway but at the cost of ~13% dilution to existing shareholders, while the company has never generated product revenue and faces ongoing confirmatory trial requirements for TUDRIQEV's accelerated approval.

Key Facts

• Offering of 9,701,490 shares of common stock at $12.06 per share and pre-funded warrants to purchase 2,736,340 shares at $12.0599 each
• Total offering size: $149,999,956; net proceeds to company: ~$140.5 million
• Pro forma shares outstanding post-offering: 92,418,413 (excluding new pre-funded warrant shares of 2,736,340)
• Immediate dilution of $9.18 per share to new investors (76% dilution from offering price to as-adjusted net tangible book value of $2.88)
• Net tangible book value before offering: $166.2 million ($1.72 per share); after offering: $306.7 million ($2.88 per share)
• FDA granted accelerated approval of TUDRIQEV (RP1) on August 6, 2026, for advanced melanoma post anti-PD-1 failure
• Going-concern warning: accumulated deficit of $1,262.5M, net loss of $313.9M in FY2026 ended March 31, 2026; cash and short-term investments of $268.9M at March 31, 2026
• Prior S-3/A filing (July 24, 2026) enabled Baker Brothers affiliates to resell up to 25,103,489 shares (~30% of pre-offering outstanding), with company receiving no proceeds

Financial Impact

Dilution of ~13% from new shares plus pre-funded warrants. Net proceeds of ~$140.5M extended cash runway by ~5-6 months at current burn rate; prior cash runway through Q1 2027 was the concern.

Risk Factors

• Dilution from new shares and pre-funded warrants, reducing EPS and ownership percentages
• Going-concern risk persists: annual net loss of $313.9M vs. cash of $268.9M; need for additional capital likely within 12 months
• TUDRIQEV accelerated approval requires confirmatory IGNYTE-3 trial; failure to confirm benefit could lead to FDA withdrawal
• Baker Brothers resale registration overhang of up to 25M shares
• Lock-up on management/insiders expires in 45 days, potentially enabling further selling

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status